What's hot
View all perspectives
What's Hot
Psoriatic Arthritis Panel: EULAR 2025
Panelists Drs. Aurelie Najm, Eric Ruderman, Nelly Ziade, Jiha Lee and Jack Cush review highlights of PsA abstracts and sessions presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
Spondyloarthritis Panel: Eular 2025
Panelists: Drs. Peter Nash, Yuz Yusof, Antoni Chan, Adela Castro and Jack Cush.
Watch video →
Steroids, Not JAKi, Are the Real Infection Risk
Dr. David Liew reporting at EULAR 2025 in Barcelona, Spain.
Watch video →
Seronegative Arthritis Breakthroughs
Dr. Janet Pope discusses abstracts POS0015, "Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors" and POS0016, "Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Psoriatic Arthritis", presented at EULAR 2025 in Barcelona, Spain.
Watch video →
JAK Safety Update
Dr. Jonathan Kay offers his perspectives on abstracts POS0150, POS0151, and POS0157 presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
Who/When to Treat Clinically Suspect Arthralgia
Dr. Jack Cush discusses risk stratification in Clinically suspect arthralgia; referencing EULAR2025 abstracts OP0004 (ALTO study) and OP0325 (long term Followup of ARRIA)
Watch video →
Hidradenitis Suppurativa: What Lies Beneath?
Dr. David Liew reports on abstract POS1237 presented at the EULAR 2025 meeting in Barcelona, Spain.
Watch video →
The Value of Kidney Biopsy in Autoimmune Diseases
Dr. Andrea Fava shares his perspective from the EULAR 2025 meeting in Barcelona, Spain.
Watch video →
ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have failed to respond to five or more biologic or targeted synthetic DMARDs. This new classification, derived from recent multinational registry data, represents a significant step in refining our understanding and management of the most treatment-resistant forms of RA.
Read more →
Two recent studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate2,3, but these did not select for poor prognosis.
Aurelie Najm AurelieRheumo
6 months 1 week ago
There is still hope for vagal nerve stimulation in RA!
RCT RESET-RA 240+pts multibioIR
Implantable cervical device
Meets Primary endpoint ACR 20 wk12
Subgroup 1 prior bioDMARD ACR 20 wk12 46% vs 19% sham
EULAR Good response 61% vs 42% sham Wk 12
SAE rate 1.7%
#OP0190 #EULAR2025 https://t.co/DCON01XXgd
Mrinalini Dey DrMiniDey
6 months 1 week ago
2-year #MANDARA data: Benralizumab shows durable remission, eosinophil suppression & OGC-sparing in EGPA. ~62-68% in remission at wk104. Low relapse rate, no loss of asthma control or decline of lung function. No new safety signals.
@RheumNow #EULAR2025 #OP0166 https://t.co/kXh2q2ilJF
Antoni Chan MD (Prof) synovialjoints
6 months 1 week ago
Difficult-to-treat & early PsA at #EULAR2025
GRAPPA definitions: D2T-PsA (≥3 therapies incl ≥2 b/tsDMARDs with persistent inflammation); C2M-PsA (broader: comorbidities, pain, intolerance). 95% GRAPPA consensus.
Abstact OP0175 @RheumNow #EULAR2025 https://t.co/eqKmMPh80x
Dr. John Cush RheumNow
6 months 1 week ago
Leeds study of 223 ACPA+ Arthralgia pts w quant. MRI of hand showing tenosynovitis (34% at baseline) doubled the risk of progression to RA. Total tenosynovitis Volume = incr. RA risk #EULAR2025 POS0472 https://t.co/eT0wbhp1uN
Dr Gurdeep S Dulay gurdeep_dulay
6 months 1 week ago
▶️Erosive hand OA
🔺Gull-wing erosion @ DIPJs ✅
🔺Saw-tooth erosions @ PIPJs ✅
#OA #Osteoarthritis #EULAR2025 https://t.co/5Hh4Ki9P8V
David Liew drdavidliew
6 months 1 week ago
Fast track PMR clinics in Denmark led to more patients seen, and time to referral went down.
If we don’t get in early with a right diagnosis (and maybe early steroid-sparing) then PMR patients deteriorate.
We shouldn’t let PMR be an end stage disease #EULAR2025 POS0136 @RheumNow https://t.co/pqwveamhJP
Mrinalini Dey DrMiniDey
6 months 1 week ago
In SLEek LTE, ABBV-599 HD (BTKi+JAKi) & UPA 30mg sustained or improved disease control through 104wks: SRI-4 ≥82%, ↓flares, near steroid-free, no new safety signals. PBO-switchers improved too. Targeted oral combos look promising.
@RheumNow #EULAR2025 #OP0198 https://t.co/IHXC2iD0h6
Adela Castro AdelaCastro222
6 months 1 week ago
Data from Dutch registry SpA-Net explored prevalence using new definitions for D2M axSpA.
-Smoking and psoriasis were characteristics associated with D2M disease.
-In the three variations explored, the lowest prevalence was observed in the variation based purely on objective https://t.co/h3f4ORQl0F
Antoni Chan MD (Prof) synovialjoints
6 months 1 week ago
Sex differences in biologic response in PsA.
DISCOVER-2 post hoc analysis showed:
•Radiographic progression at Week
♂️: 2.22 units
♀️: 1.10 units
•Early ACR-like response (cDAPSA LDA at 8wks) linked to less damage in men (0.39 vs 2.24)
Women less likely to progress https://t.co/NhBkXbuLjO
Md Yuzaiful Md Yusof Yuz6Yusof
6 months 1 week ago
#EULAR2025 Abstr#OP0006. There is no standardised definition for complete renal response in #lupus nephritis. Post-hoc analysis of REGENCY showed Obinutuzumab + SOC was superior to PBO + SOC if endpoints for voclosporin and belimumab RCTs were used. Effect size ~13-16% @RheumNow https://t.co/q8MNAV8XF3
Dr. John Cush RheumNow
6 months 1 week ago
Secukinumab Use in Refractory Giant Cell Arteritis
In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/pG3aN3o4GZ
Janet Pope Janetbirdope
6 months 1 week ago
T2T in #gout w serum #uric #acid / #urate target
SAVES LIVES
Study of achievement of target 🎯
⬇️CVE and death
If not achieving Urate <360
T2T also reduced baseline #SUA
#EULAR2025 @rheumnow abst#OP0005 https://t.co/ePchJ4vqnU
Janet Pope Janetbirdope
6 months 1 week ago
#Oninutuzumab works in
#lupus #nephritis #LN
no matter how you vary the
#renal #responses
Of various definitions of
#Complete & #Partial #renal #responses
abst#OP0006
#EULAR25 @eular_org @RheumNow
Not surprised 😲 https://t.co/Zn2lXkddez
Janet Pope Janetbirdope
6 months 1 week ago
1 shot will do!
#symptomatic #Knee #OA given #gene #therapy #intra-#articular
Seemed to last up to 104 weeks!
But no placebo
small safety study but sustained #WOMAC responses
Needs large #RCT but v interesting
#EULAR2025 @RheumNow @eular_org
Abst# POS0492 https://t.co/hqTqBorrbA
Poster Hall